Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment

MG Mazza, M Palladini, S Poletti, F Benedetti - CNS drugs, 2022 - Springer
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide
over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors …

[HTML][HTML] Fluvoxamine: a review of its mechanism of action and its role in COVID-19

VP Sukhatme, AM Reiersen, SJ Vayttaden… - Frontiers in …, 2021 - frontiersin.org
Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake
inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized …

Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study

N Hoertel, M Sánchez-Rico, R Vernet, N Beeker… - Molecular …, 2021 - nature.com
A prior meta-analysis showed that antidepressant use in major depressive disorder was
associated with reduced plasma levels of several pro-inflammatory mediators, which have …

Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants

T Oskotsky, I Marić, A Tang, B Oskotsky… - JAMA network …, 2021 - jamanetwork.com
Importance Antidepressant use may be associated with reduced levels of several
proinflammatory cytokines suggested to be involved with the development of severe COVID …

Mechanisms of action of fluvoxamine for COVID-19: a historical review

Y Hashimoto, T Suzuki, K Hashimoto - Molecular psychiatry, 2022 - nature.com
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of …

The acid sphingomyelinase/ceramide system in COVID-19

J Kornhuber, N Hoertel, E Gulbins - Molecular psychiatry, 2022 - nature.com
Acid sphingomyelinase (ASM) cleaves sphingomyelin into the highly lipophilic ceramide,
which forms large gel-like rafts/platforms in the plasma membrane. We showed that SARS …

The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial

M Shohan, R Nashibi, MR Mahmoudian-Sani… - European journal of …, 2022 - Elsevier
In this study, the therapeutic efficacy of quercetin in combination with remdesivir and
favipiravir, were evaluated in severe hospitalized COVID-19 patients. Our main objective …

[HTML][HTML] Recent advances in management of COVID-19: A review

S Mouffak, Q Shubbar, E Saleh, R El-Awady - Biomedicine & …, 2021 - Elsevier
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused and is still causing
significant mortality and economic consequences all over the globe. As of today, there are …

Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: an open label, prospective cohort trial with matched controls

M Calusic, R Marcec, L Luksa, I Jurkovic… - British journal of …, 2022 - Wiley Online Library
Aims Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) and sigma‐1 receptor
agonist, has so far shown promise in the prevention of COVID‐19 progression as an early …

COVID-19-related mortality risk in people with severe mental illness: a systematic and critical review

M De Hert, V Mazereel, M Stroobants… - Frontiers in …, 2022 - frontiersin.org
Background: Increasing clinical evidence suggests that people with severe mental illness
(SMI), including schizophrenia spectrum disorders, bipolar disorder (BD), and major …